Disclosed is the use of glatiramer acetate for the manufacture of a medicament comprising a 40 mg dose of glatiramer acetate for treating a patient who is suffering from relapsing remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament is adapted for administration in a regimen of three subcutaneous injections over a period of seven days with at least one day between each subcutaneous injection.
